Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | CASP3 | P42574 | 4/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 4/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 4/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21027551 | 0.80 | ALDH1A1 (0.73) | RAB9ANPC1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL11475412 | 0.77 | CASP3 (0.58) | RAB9ANPC1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL30620627 | 0.76 | NPC1 (0.60) | RAB9ANPC1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL27817990 | 0.76 | NPC1 (0.60) | RAB9ANPC1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL10697623 | 0.76 | SMN1; SMN2 (0.57) | RAB9ANPC1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL23812437 | 0.75 | ALDH1A1 (0.69) | RAB9ANPC1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL11377704 | 0.74 | SMN1; SMN2 (0.66) | RAB9ANPC1SMN1; SMN2LMNAALDH1A1 | |
| Iodomethane SCHEMBL11482698 | 0.74 | CASP3 (0.54) | RAB9ANPC1SMN1; SMN2LMNAALDH1A1 | |
| Iodomethane SCHEMBL11477652 | 0.74 | RAB9A (0.54) | RAB9ANPC1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL6708912 | 0.74 | NPC1 (0.70) | RAB9ANPC1SMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266871-A1 | Methods for treating alzheimer's disease using quinaldoyl-amine derivatives of oxo-and hydroxy-substituted hydrocarbons | PHARMACIA & UPJOHN | 2004-12-30 | — | — | US | disclosed |
| EP-0633881-B1 | AMINE DERIVATIVES OF OXO- AND HYDROXY-SUBSTITUED HYDROCARBONS | NARHEX LTD (HK) | 2003-10-29 | — | — | EP | disclosed |
| EP-0801640-B1 | 2,5-DIAMINO-3,4-DISUBSTITUTED-1,6-DIPHENYLHEXANE ISOSTERES COMPRISING BENZAMIDE, SULFONAMIDE AND ANTHRANILAMIDE SUBUNITS AND METHODS OF USING SAME | USA (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6258806-B1 | PEPTIDES WITH CYCLIC DIAZAALKANES FOR PREVENTION OF PREMATURE METABOLISM METHOD FOR INHIBITING AN HIV PROTEASE IN A MAMMAL IN NEED OF SUCH PROTEASE INHIBITION, COMPRISING ADMINISTERING TO SAID MAMMAL AN EFFECTIVE DOSAGE | NARHEX LIMITED (HK) | 2001-07-10 | — | — | US | disclosed |
| US-6066656-A | IN VITRO METHOD OF ASSAYING FOR ANTIRETROVIRAL ACTIVITY OF A COMPOUND BY MEASURING THE FLUORESCENCE OF A FLUORESCENT COMPOUND, MEASURING THE CHANGE IN FLUORESCENCE OF SAID COMPOUND IN THE PRESENCE OF A RETROVIRAL PROTEASE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-05-23 | — | — | US | disclosed |
| US-5942504-A | INHIBITORS OF RETROVIRAL PROTEASES; TREATMENT OF AIDS AND HIV | NARHEX LIMITED (HK) | 1999-08-24 | — | — | US | disclosed |
| US-5925780-A | VIRICIDES FOR RETROVIRAL SPECIES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-07-20 | — | — | US | disclosed |
| US-5728718-A | RETROVIRAL PROTEASE INHIBITOR; TREATMENT OF HTLV | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-03-17 | — | — | US | disclosed |
| EP-0801640-A1 | 2,5-DIAMINO-3,4-DISUBSTITUTED-1,6-DIPHENYLHEXANE ISOSTERES COMPRISING BENZAMIDE, SULFONAMIDE AND ANTHRANILAMIDE SUBUNITS AND METHODS OF USING SAME | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1997-10-22 | — | — | EP | disclosed |
| US-5679688-A | RETROVIRAL PROTEASE INHIBITORS; AIDS THERAPY | NARHEX LIMITED (HK) | 1997-10-21 | — | — | US | disclosed |
| WO-1996019437-A9 | 2,5-DIAMINO-3,4-DISUBSTITUTED-1,6-DIPHENYLHEXANE ISOSTERES COMPRISING BENZAMIDE, SULFONAMIDE AND ANTHRANILAMIDE SUBUNITS AND METHODS OF USING SAME | — | 1996-09-06 | — | — | WO | disclosed |
| WO-1996019437-A1 | 2,5-DIAMINO-3,4-DISUBSTITUTED-1,6-DIPHENYLHEXANE ISOSTERES COMPRISING BENZAMIDE, SULFONAMIDE AND ANTHRANILAMIDE SUBUNITS AND METHODS OF USING SAME | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-06-27 | — | — | WO | disclosed |
| EP-0633881-A4 | AMINE DERIVATIVES OF OXO- AND HYDROXY-SUBSTITUED HYDROCARBONS. | — | 1995-02-22 | — | — | EP | disclosed |
| EP-0633881-A1 | AMINE DERIVATIVES OF OXO- AND HYDROXY-SUBSTITUED HYDROCARBONS | Narhex Limited (HK) | 1995-01-18 | — | — | EP | disclosed |
| WO-1993018006-A1 | AMINE DERIVATIVES OF OXO- AND HYDROXY-SUBSTITUED HYDROCARBONS | NARHEX LIMITED (HK) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266871-A1 | Methods for treating alzheimer's disease using quinaldoyl-amine derivatives of oxo-and hydroxy-substituted hydrocarbons | BACE1, BACE2, PSEN1 | RAB9A 1654/4885NPC1 308/4885SMN1; SMN2 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.